by Renato D. Lopes, Patrícia O. Guimarães, Bradley J. Kolls, Daniel M

Slides:

Advertisements

Similar presentations

Apixaban versus Aspirin in Atrial Fibrillation Patients ≥ 75 years old: An Analysis from the AVERROES Trial Kuan H Ng, Olga O Shestakovska, John W. Eikelboom,

Advertisements

PROTECT-AF (LAA Closure with Watchman vs Warfarin in AF and Stroke) A long-term (45-month) follow-up analysis of device therapy with Watchman vs warfarin.

Efficacy and safety of apixaban compared with warfarin at different levels of INR control for stroke prevention in atrial fibrillation.

ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

Shinya Goto,1 Jun Zhu,2 Liu Lisheng,2 Byung-Hee Oh,3 Daniel M. Wojdyla,4 Michael Hanna,5 John D. Horowitz,6 Lars Wallentin,7 Denis Xavier,8 John H. Alexander4.

Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura by Donald M. Arnold, Ishac Nazi, Aurelio Santos,

Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study by Cheng E. Chee, Aneel A. Ashrani,

Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes.

Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Choice of Antithrombotic Therapy for Stroke Prevention.

Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective by Michael D. Ezekowitz, Rangadham.

Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated with Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.

Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated.

Heart, Lung and Circulation

A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfety and.

American Heart Journal

Volume 28, Issue 6, Pages (December 2012)

Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Emily C. O’Brien, PhD,

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.

Circ Arrhythm Electrophysiol

by Anuj Shah, Anand Shewale, Corey J. Hayes, and Bradley C. Martin

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

Central venous line–related thrombosis in children: association with central venous line location and insertion technique by Christoph Male, Peter Chait,

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

Improved outcome in central nervous system aspergillosis, using voriconazole treatment by Stefan Schwartz, Markus Ruhnke, Patricia Ribaud, Lawrence Corey,

by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa

Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura

by Renato D. Lopes, John D. Horowitz, David A. Garcia, Mark A

Finding a diamond in the (mouse is) rough

by James O. Armitage, and Dan L. Longo

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy by Chun.

How I treat elderly patients with myeloma

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

Functional neutrophils from human ES cells

Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.

by Alexander Röth, Andreas Hüttmann, Russell P

Left atrial appendage closure: A new technique for clinical practice

by Sabah Sallah, and Jim Y. Wan

Daniel Frenkel et al. JACEP 2016;2:

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lymphoma.

Blocking VWF platelet binding to treat TTP

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience by Daryl Tan, Sandra.

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Anergy: the CLL cell limbo

Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update Mate Vamos, MD, PhD, Julia Wiebke Erath,

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Truman J. Milling, MD, Alex C. Spyropoulos, MD

Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review Truman.

John P. Vavalle, MD, MHS, Renato D. Lopes, MD, PhD, Anita Y

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Renato D. Lopes, MD, PhD on behalf of the.

ACC 2003 Late Breaking Trials

P. Michael Grossman et al. JCIN 2009;2:

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.

Treatment versus Transplant for Challenging Hematologic Disorders

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis by Rasha Khatib, Maja Ludwikowska, Daniel.

Effect of randomized treatment on all renal events (top) and the composite of all renal events, macrovascular events, or all-cause mortality (bottom) according.

Gianluigi Savarese et al. JCHF 2016;4:

Balancing bleeding in brain metastases

New concepts for anticoagulant therapy in persons with hemophilia

Presentation transcript:

Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy by Renato D. Lopes, Patrícia O. Guimarães, Bradley J. Kolls, Daniel M. Wojdyla, Cheryl D. Bushnell, Michael Hanna, J. Donald Easton, Laine Thomas, Lars Wallentin, Sana M. Al-Khatib, Claes Held, Pedro Gabriel Melo de Barros e Silva, John H. Alexander, Christopher B. Granger, and Hans-Christoph Diener Blood Volume 129(22):2980-2987 June 1, 2017 ©2017 by American Society of Hematology

Rates of ICH by location, type, and randomized treatment. Rates of ICH by location, type, and randomized treatment. The benefits of apixaban over warfarin in causing significantly less ICH was consistent regardless of type and location of ICH. Renato D. Lopes et al. Blood 2017;129:2980-2987 ©2017 by American Society of Hematology

Thirty-day all-cause mortality after ICH event by randomized treatment. Thirty-day all-cause mortality after ICH event by randomized treatment. Similar rates of all-cause mortality following ICH were observed in apixaban- and warfarin-treated patients. Renato D. Lopes et al. Blood 2017;129:2980-2987 ©2017 by American Society of Hematology